Abstract
Founder events influence recessive diseases in highly endogamous populations. Several Indian populations have experienced significant founder events and maintained strict endogamy. Genomic studies in Indian populations often lack in addressing clinical implications of these phenomena. We performed whole-exome sequencing of 281 individuals from four South Indian groups to evaluate population-specific disease causing mutations associated with founder events. Our study revealed a high inbreeding rate of 59% across the groups. We identified ∼29.2% of the variants to be exclusive to a single population and uncovered 1,284 novel exonic variants, underscoring the genetic underrepresentation of Indian populations. Among these, 23 predicted as deleterious were found in heterozygous state, suggesting they may be pathogenic in a homozygous state and are common in the endogamous groups. Approximately 40-68% of the identified pathogenic variants showed significantly higher occurrence rates. Pharmacogenomic analysis revealed distinct allele frequencies in CYP450 and non-CYP450 gene variants, highlighting heterogeneous drug responses and associated risks. We report a high prevalence of ankylosing spondylitis in Reddys, linked to HLA-B*27:04 allele and strong founder effect. Our findings emphasize the need for expanded genomic research in understudied Indian populations to elucidate disease risk and medical profiles, eventually aiming towards precision medicine and mitigating disease burden.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
PM was supported by the DBT JRF-SRF research fellowship. KT was supported by J C Bose Fellowship from Science and Engineering Research Board (SERB), Department of Science and Technology (JCB/2019/000027).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Ethical Committees of the Centre for Cellular and Molecular Biology, Hyderabad, India gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The raw sequence data for the samples included in this study has been submitted under the BioProject ID PRJNA1112977 (to be released on manuscript publication).